21 completed, 8 terminated. 29 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 29 | Completed 21, Terminated 8 |
| Phase 2 | 3 | Terminated 2, Completed 1 |
Follow Stage IV Marginal Zone Lymphoma: new trials by email Literature Review of Stage IV Marginal Zone Lymphoma trials Research Report on Stage IV Marginal Zone Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas lenalidomide, etoposide, prednisone - Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | University of Chicago | 55 | 2014-07-29 | 2026-03-11 |
| Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas brentuximab vedotin, rituximab, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 / Phase 2 | Terminated | Northwestern University | 20 | 2013-03-05 | 2021-09-01 |
| RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors gamma-secretase/Notch signalling pathway inhibitor RO4929097, capecitabine, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 2010-06-01 | 2014-11-07 |
| AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma Pharmacodynamic Studies, Fatigue Inventory, Pharmacogenomic studies - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Completed | Amir Mortazavi | 44 | 2010-05-04 | 2018-06-04 |
| Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma lenalidomide, rituximab, polymerase chain reaction - Adult Non-Hodgkin Lymphoma, Adult Grade III Lymphomatoid Granulomatosis | Phase 1 | Terminated | Case Comprehensive Cancer Center | 5 | 2010-01-01 | 2015-11-26 |
| Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery R-(-)-gossypol acetic acid, paclitaxel, carboplatin - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 36 | 2009-07-01 | 2013-01-10 |
| FAU in Treating Patients With Advanced Solid Tumors or Lymphoma 2'-F-ara-deoxyuridine, positron emission tomography, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 12 | 2009-07-01 | 2014-01-07 |
| Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery Dasatinib, Pharmacological Study - Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 80 | 2008-10-01 | 2015-07-02 |
| Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction vorinostat, pharmacological study - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 15 | 2007-06-01 | 2014-02-24 |
| 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma gemcitabine hydrochloride, triapine - Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 2006-06-01 | 2013-09-30 |
| PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma tanespimycin, belinostat, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 36 | 2006-05-01 | 2013-05-16 |
| PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas belinostat, bortezomib, pharmacological study - Adult Grade III Lymphomatoid Granulomatosis, Anaplastic Large Cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 55 | 2006-03-01 | 2013-05-03 |
| Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia vorinostat, decitabine - Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Phase 1 | Completed | National Cancer Institute (NCI) | 80 | 2006-02-01 | 2014-08-27 |
| Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma fenretinide, rituximab - Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma, B-cell Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 32 | 2005-10-01 | 2014-10-06 |
| Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas tanespimycin, bortezomib, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, AIDS-related Peripheral/Systemic Lymphoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 36 | 2004-11-01 | 2014-02-24 |
| SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma ispinesib, laboratory biomarker analysis, pharmacological study - Adult Grade III Lymphomatoid Granulomatosis, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Phase 1 | Terminated | National Cancer Institute (NCI) | 31 | 2004-11-01 | 2013-01-14 |
| MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas entinostat, isotretinoin - Adult Grade III Lymphomatoid Granulomatosis, Anaplastic Large Cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 24 | 2004-10-01 | 2013-01-24 |
| Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function sorafenib tosylate, pharmacological study - Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 150 | 2004-10-01 | 2013-01-07 |
| 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas alvespimycin hydrochloride, laboratory biomarker analysis - Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 60 | 2004-07-01 | 2013-01-25 |
| Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma cilengitide - AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 45 | 2003-12-01 | 2013-01-24 |
Showing 20 of 29. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (29) · Lymphoma, B-Cell, Marginal Zone (29) · Lymphoma, Follicular (28) · Lymphoma, Mantle-Cell (28) · Lymphoma, Large B-Cell, Diffuse (27) · Burkitt Lymphoma (26) · Lymphoma, Non-Hodgkin (26) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (26) · Lymphoma, Large-Cell, Immunoblastic (25) · Waldenstrom Macroglobulinemia (21) · Hodgkin Disease (20) · Lymphoma, T-Cell, Cutaneous (17) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (17) · Immunoblastic Lymphadenopathy (16) · Lymphoma, Large-Cell, Anaplastic (16)
Chronic Disease (29) · Disease Attributes (29) · Hematologic Diseases (29) · Hemic and Lymphatic Diseases (29) · Immune System Diseases (29) · Immunoproliferative Disorders (29) · Leukemia (29) · Leukemia, B-Cell (29) · Leukemia, Lymphoid (29) · Lymphatic Diseases (29) · Lymphoma (29) · Lymphoma, B-Cell (29) · Lymphoproliferative Disorders (29) · Neoplasms (29) · Neoplasms by Histologic Type (29)
Rituximab (6) · tanespimycin (4) · Bortezomib (3) · Gemcitabine (2) · Lenalidomide (2) · Pharmacogenomic Testing (2) · Vorinostat (2) · belinostat (2) · 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (1) · 2'-fluoro-5-ethylarabinosyluracil (1) · 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (1) · 2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole (1) · 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (1) · Amplified Fragment Length Polymorphism Analysis (1) · Base Sequence (1)
National Cancer Institute (NCI) (25) · Amir Mortazavi (1) · Case Comprehensive Cancer Center (1) · Northwestern University (1) · University of Chicago (1)
United States (28) · Canada (2)
John Byrd (2) · Patricia LoRusso (2) · Ramesh Ramanathan (2) · Adam Petrich, MD (1) · Ajay Gopal (1) · Amir Mortazavi, MD (1) · Antonius Miller (1) · Chandra Belani (1) · Charles Erlichman (1) · Daniel Mulkerin (1) · George Wilding (1) · Jean Grem (1) · John Sarantopoulos (1) · Karen Yee (1)
PMID 26943915, PMID 28270022, PMID 31388792, PMID 33492438, PMID 40720747
U01CA062487 (5), U01CA062491 (5), U01CA099168 (5), U01CA076576 (4), U01CA062502 (3), U01CA062505 (3), U01CA069852 (2), U01CA069912 (2), U01CA132123 (2), N01CM62208 (1), P30CA014520 (1), P30CA014599 (1), P30CA015083 (1), P30CA016058 (1), P30CA022453 (1)